Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (291-300 of 388) with videos related to

Pageof 39
Sort By:
Oncology|January 17, 2015
Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trialCora N Sternberg, Fabio Calabrò, Sergio Bracarda, et al.
Pathology|February 29, 2020
Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targetsAnna Caliò, Matteo Brunelli, Diego Segala, et al.
The Lancet. Oncology|June 10, 2022
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trialRobert J Motzer, Thomas Powles, Mauricio Burotto, et al.
Plos One|April 12, 2016
Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective AnalysisPaolo Grassi, Ludovic Doucet, Palma Giglione, et al.
Targeted Oncology|January 7, 2015
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapyMatteo Santoni, Sebastiano Buti, Alessandro Conti, et al.
Cancers|December 3, 2020
An Anti-MICA/B Antibody and IL-15 Rescue Altered NKG2D-Dependent NK Cell Responses in Hepatocellular CarcinomaStefania Mantovani, Stefania Varchetta, Dalila Mele, et al.
Cancer Research|November 8, 2013
Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggeringAna I Romero, Nathalie Chaput, Vichnou Poirier-Colame, et al.
Targeted Oncology|November 15, 2015
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory AnalysisFrancesco Massari, Chiara Ciccarese, Anna Caliò, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|June 5, 2010
The impact of antithrombotic prophylaxis on infectious complications in cancer patients with central venous catheters: an observational studyDaniele Fagnani, Alessandro Bertolini, Laura Catena, et al.
Oncotarget|September 1, 2016
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinibLorenza Rimassa, Giovanni Abbadessa, Nicola Personeni, et al.
Pageof 39

Showing results (291-300 of 388) with videos related to

Sort By:
Pageof 39
Oncology|January 17, 2015
Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trialCora N Sternberg, Fabio Calabrò, Sergio Bracarda, et al.
Pathology|February 29, 2020
Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targetsAnna Caliò, Matteo Brunelli, Diego Segala, et al.
The Lancet. Oncology|June 10, 2022
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trialRobert J Motzer, Thomas Powles, Mauricio Burotto, et al.
Plos One|April 12, 2016
Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective AnalysisPaolo Grassi, Ludovic Doucet, Palma Giglione, et al.
Targeted Oncology|January 7, 2015
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapyMatteo Santoni, Sebastiano Buti, Alessandro Conti, et al.
Cancers|December 3, 2020
An Anti-MICA/B Antibody and IL-15 Rescue Altered NKG2D-Dependent NK Cell Responses in Hepatocellular CarcinomaStefania Mantovani, Stefania Varchetta, Dalila Mele, et al.
Cancer Research|November 8, 2013
Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggeringAna I Romero, Nathalie Chaput, Vichnou Poirier-Colame, et al.
Targeted Oncology|November 15, 2015
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory AnalysisFrancesco Massari, Chiara Ciccarese, Anna Caliò, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|June 5, 2010
The impact of antithrombotic prophylaxis on infectious complications in cancer patients with central venous catheters: an observational studyDaniele Fagnani, Alessandro Bertolini, Laura Catena, et al.
Oncotarget|September 1, 2016
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinibLorenza Rimassa, Giovanni Abbadessa, Nicola Personeni, et al.
Pageof 39